MNPR, US61023L2079

Monopar Therapeutics stock fell 3.52 percent on Nasdaq

Published on 10/17/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due on November 12, 2026. Monopar Therapeutics stock stood at USD 69.27 on October 16, 2026, down 3.52 percent on Nasdaq.

Stock move and upcoming date

Monopar Therapeutics stock fell 3.52 percent on Nasdaq on October 16, 2026.
Quarterly results are scheduled for November 12, 2026.
Monopar Therapeutics stock stood at USD 69.27 on October 16, 2026, down 3.52 percent on Nasdaq.
The stock traded within a USD 50.07 to USD 124.82 52-week range.

MNPR, US61023L2079, Illustration mit AI erstellt.

Monopar Therapeutics stock fell 3.52 percent on Nasdaq on October 16, 2026, after the shares moved from USD 71.80 to USD 69.27 during the completed session. The move was measured against the Nasdaq prior close and puts the stock well inside its yearly range. Results are due on November 12, 2026.

November 12 reporting date

The next earnings report is expected on November 12, 2026, according to MetaCap. Monopar's investor-relations page identifies the latest reported period as the second quarter ended June 30, 2026 and presents the company as a clinical-stage biotechnology business developing radiopharmaceuticals and treatments for Wilson Disease.

USD 50.07 to USD 124.82 range

The stock's 52-week range was USD 50.07 to USD 124.82 as of October 16, 2026. At USD 69.27, the shares stood USD 55.55, or 44.50 percent, below the yearly high and USD 19.20, or 38.34 percent, above the yearly low. Trading volume reached 142,398 shares, versus an average volume of 204,229 shares, a difference of 30.27 percent.

Monopar's October 16 move was larger than the 1.11 percent decline in the SPDR S&P 500 ETF on the same date. The biotech company had a market capitalization of USD 465.0 million and a negative P/E ratio of minus 29.60. Its clinical pipeline includes MNPR-101-Zr for imaging and MNPR-101-Lu for radiopharmaceutical treatment, while ALXN1840 is being developed for Wilson Disease.

Valuation at USD 465.0 million

The valuation snapshot places Monopar among small-cap biotechnology companies, with a market capitalization of USD 465.0 million as of October 16, 2026. The company reported 22 full-time employees in its structured company profile, while its investor-relations materials describe a development model built around internal programs and licensed therapies.

Comparison with peers

Monopar Therapeutics (Nasdaq, USD): minus 3.52 percent, P/E minus 29.60, market capitalization USD 465.0 million.
ALX Oncology Holdings (Nasdaq, USD): plus 6.00 percent, P/E minus 0.94, market capitalization USD 146.6 million.
SPDR S&P 500 ETF (NYSE Arca, USD): minus 1.11 percent, market capitalization USD 814.0 billion.

Price remains below yearly high

For investors, the key market fact is the gap between the latest Nasdaq level and the 52-week high. The next scheduled report on November 12, 2026 supplies the next dated checkpoint for the clinical-stage company.

The latest Nasdaq price stood at USD 69.27 on October 16, 2026 at 4:00 p.m. EDT, down 3.52 percent versus the Nasdaq prior close.